Urogen Pharma Stock Earnings Reports

UroGen reported strong Q1 2026 results driven by the early commercial launch of ZUSDURI and continued steady demand for JELMYTO. Key commercial highlights: ZUSDURI generated $29.2M in revenue ( >100% quarter-over-quarter growth), unique prescribers increased to 256 (from 102 at year-end) and repeat prescribers to 103 (from 32). The permanent J-code effective January 1, 2026 is cited as a major inflection point enabling broader access (open access to >95% of covered lives) and faster adoption in community practices (mix shifting toward ~50% community at quarter end). Conversion times from patient enrollment form to treatment are improving (from ~45–60 days in prior quarters to ~30–35 days in Q1, with an expectation to reach ~2–3 weeks steady state). Management views ZUSDURI as addressing an estimated $5B annual market opportunity with potential to exceed $1B peak annual revenue at modest penetration. JELMYTO revenue was $21.7M and is expected to grow modestly (guidance unchanged at $97M–$101M for 2026). Pipeline progress: NDA for UGN-103 planned for H2 2026 (potential approval 2027), UGN-104 Phase III enrollment expected to complete by end of 2026, and IND for oncolytic UGN-501 planned in Q2 with Phase I initiation by year-end. Financials: total revenue $51.0M (up 152% YoY), R&D expense down to $15.6M, SG&A up to $51.5M reflecting commercial investment, net loss $23.6M ($0.47/share), and cash, cash equivalents and marketable securities of $140.3M. Full-year 2026 operating expense guidance: $240M–$250M (including $20M–$24M of noncash stock comp). Management emphasizes continued launch execution, expansion into community sites, improvement in conversion timelines, targeted patient-directed awareness, and disciplined investment in pipeline with cash runway to profitability.